ダウンロード数: 0

このアイテムのファイル:
このアイテムは一定期間後に公開されます。
公開日については,アイテム画面の「著作権等」でご確認ください。
タイトル: 尿路感染症による敗血症性DICに対する遺伝子組み換えトロンボモジュリンの有効性についての検討
その他のタイトル: Efficacy of Recombinant Thrombomodulin for Sepsis-Associated Disseminated Intravascular Coagulation Caused by Urinary Tract Infections
著者: 橘, 進彰  KAKEN_name
飯田, 孝太  KAKEN_name
伊丹, 祥隆  KAKEN_name
橋村, 正哉  KAKEN_name
豊島, 優多  KAKEN_name
細川, 幸成  KAKEN_name
藤本, 清秀  KAKEN_name
著者名の別形: TACHIBANA, Akira
IIDA, Kota
ITAMI, Yoshitaka
HASHIMURA, Masaya
TOYOSHIMA, Yuta
HOSOKAWA, Yukinari
FUJIMOTO, Kiyohide
キーワード: Disseminated intravascular coagulation
Recombinant thrombomodulin
Urinary tract infection
発行日: 30-Nov-2023
出版者: 泌尿器科紀要刊行会
誌名: 泌尿器科紀要
巻: 69
号: 11
開始ページ: 309
終了ページ: 314
抄録: Severe urinary tract infections occasionally cause sepsis and disseminated intravascular coagulation (DIC). We examined the efficacy of recombinant thrombomodulin (rTM) for treating DIC caused by urosepsis. We enrolled 40 patients who were diagnosed with DIC caused by urosepsis at our hospital between April 2018 and May 2022. Twenty-six patients were treated with rTM (rTM group), while 14 patients did not receive rTM (non-rTM group). The DIC score before treatment in the rTM group was significantly higher than that in the non-rTM group (P<0.01). There was no significant difference in disease-specific survival between the two groups. There was a significant improvement in DIC scores on days 1-3 after administering rTM. However, the duration of DIC in the rTM group was significantly longer than that in the non-rTM group (P=0.038). The administration of rTM may have benefits in patients with DIC caused by urosepsis.
著作権等: 許諾条件により本文は2024-12-01に公開
DOI: 10.14989/ActaUrolJap_69_11_309
URI: http://hdl.handle.net/2433/286244
PubMed ID: 38031329
出現コレクション:Vol.69 No.11

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。